Background: The hepatitis C virus (HCV) epidemic is particularly devastating in Egypt where its prevalence is about 12%. Chronic HCV infection can result in the accumulation of immune complexes and stimulate antibodies, which can result in extrahepatic manifestations (EHM).
Introduction
An estimated 170 million individuals (3%) worldwide are chronically infected with the hepatitis C virus (HCV) [1, 2] . In the absence of treatment, 20% of them will develop cirrhosis or cancer [1, 3] .
The HCV epidemic is particularly devastating in Egypt where the prevalence of HCV infection is about 12% [4, 5] . HCV infection should be regarded as a systemic infectious disease with multiorgan involvement. More than 50% of HCVpositive patients develop during the course of the disease at least one extrahepatic manifestation (EHM). The EHMs are often the first and only clinical signs of a chronic hepatitis C [6, 7] . Evidence of HCV infection should always be sought out in cases of unspecific chronic fatigue and/or rheumatic, hematological, endocrine or dermatological disorders. It has been reported to be associated with various rheumatic diseases in Egypt as rheumatoid arthritis [8] , systemic lupus erythematosus [9] and vasculitis [10] .
The goal of antiviral HCV therapy is to cure the infection via a sustained elimination of the virus and to prevent liver fibrosis and end stage liver diseases (cirrhosis and hepatocellular carcinoma) [11] . The standard of care (SOC) for patients with chronic hepatitis C virus (HCV) infection has consisted of a combination of pegylated interferon (INF) plus ribavirin, administered for 24-48-weeks depending on the HCV genotype. HCV therapy has been revolutionised by the approval of two direct-acting antiviral agents (DAA) against the NS3/ 4A serine protease for use in genotype 1 HCV, the protease inhibitors boceprevir and telaprevir [12] . Accordingly, this study aimed to assess the efficacy and safety of combined pegylated interferon and ribavirin therapy in the management of rheumatological extrahepatic manifestations in HCV patients.
Patients and methods
Fifty consecutive unselected HCV patients with rheumatologic extrahepatic manifestations were included in this study, from the Rheumatology and Rehabilitation outpatient clinic, inpatient department, Faculty of Medicine, Cairo University hospitals and El-Kahera Al-fatemia hospital. Inclusion criteria for the study were as follows: (a) Chronic HCV infection; (b) The presence of HCV rheumatological extrahepatic manifestations; Exclusion criteria were: (a) The presence of hepatitis B surface antigen; (b) The presence of rheumatic autoimmune disease.
Treatment schedule consisted of weekly administration of antiviral combination: Peginterferon (180 lg SC/week, or 1.5 lg/kg/week) + ribavirin 1000-1250 mg/day for at least 6 months. Informed consent was obtained for each patient and the study was approved by the local ethics committee and has been carried out in accordance with the declaration of Helsinki. Out of our 50 patients; twenty-three patients were contraindicated to receive interferon (Five patients were above 60 years of age; Eight patients had decompensated liver disease; Three patients had severe anemia and not improved after a course of iron supplement; 2 patients had coronary heart disease, 1 patient with psoriasis and 3 patients could not reduce their body mass index to the range emitting administration of interferon). The remaining 27 patients received treatment for at least 6 months.
Before starting the antiviral combination all patients were subjected to: full history taking, clinical examination (general and full joint examination), calculation of the disease activity score in 28 joints (DAS28) [13] , complete laboratory investigations including: complete blood count (CBC), erythrocyte sedimentation rate (ESR), serum rheumatoid factor (RF) by the latex agglutination method, detection of circulatory antinuclear antibodies (ANA) using the immunofluorescence technique, Liver function tests (alanine transaminase 'ALT', aspartate transaminase 'AST', serum albumin, alkaline phosphatase), kidney function tests (urea, creatinine), complete urine analysis and cryoglobulins, and quantitative reverse transcriptase polymerase chain reaction (RT-PCR) (Applied Biosystems, USA). Follow up of each patient includes: weekly CBC and liver function tests during the first month, then monthly. After 12 weeks of treatment the quantitative PCR, liver function tests, kidney function tests, TSH and fundus examination were repeated. Treatment efficacy: the response to treatment was analyzed by comparing clinical, virologic and immunologic parameters at the initial evaluation and at the end of 6 months of antiviral treatment (AVT).
Statistical analysis: Data were coded and entered using the statistical package SPSS version 15. Data were summarized using descriptive statistics: mean ± standard deviation (±SD), or frequencies (n) and percentages (%). Statistical differences between groups were tested using Chi Square test (v2) and McNemar test for qualitative variables, Independent sample t-test and ANOVA (analysis of variance) for quantitative normally distributed variables and non-parametric Mann-Whitney test and Kruskal Wallis test for non-normally distributed quantitative variables. Correlations were done to test for linear relations between variables. A probability value (p value) <0.05 was considered statistically significant.
Results
The 27 HCV patients with extrahepatic manifestations who received combined antiviral therapy for at least 6 months included 6 men and 21 women with a mean age of 43.8 ± 7.6 years (range 32-59 years). Main characteristics of the 27 patients are detailed in Tables 1-3 .
Treatment related data and outcomes: 6 months following antiviral therapy, 15 patients (55.5%) had sustained virologic response (SVR) and 4 (from a total of 16) (25%) had complete biochemical response. Concerning the clinical response; 2 patients (7.4%) were complete clinical responders (CR), 5 patients (18.5%) were partial responders (PR), 3 patients (11.1%) showed relapse and 17 (63%) were non-responders (NR) ( Fig. 1) .
A comparison of DAS28 score interpretations before and after (AVT) among the 23 patients with joint arthropathy showed a p value of 0.05. Final DAS 28 response criteria (joint response) revealed: 2 patients only (8.7%) had a good joint response, 7 (30.4%) had a moderate joint response, while 14 (60.8%) had no response. Joint affection showed improvement in only 2 patients (8.6%) of 23, while 2 patients free of joint affection developed arthropathy with AVT; 1 developed arthritis in both knees and 4 PIPs and the other patient developed arthralgias of all PIPs. 23 patients had joint arthropathy (85.5%). 13/23(56.5%) had bilateral symmetric non-deforming polyarthritis and asymmetric oligoarthropathy was noticed in 10 patients (43.4%). 4 patients had peripheral neuropathy (PN); 3 showed stationary course of PN and one became worse. The percentage change in liver enzymes, PCR positivity, fatigue, cryoglobulins, peripheral neuritis, skin affection and arthropathy is presented in Fig. 2 . The 23 patients with joint affection were treated with anti-inflammatory or disease modifying anti-rheumatic drugs for a variable duration before and during AVT. These regimens included NSAIDs (n = 23), steroids (n = 5), methotrexate (n = 6), hydroxychloroquine (n = 22) and sulfasalazine (n = 5). All 5 patients with vasculitis were initially treated with steroids, 3 patients were treated with azathioprine, 2 patients with cyclophosphamide and plasmapheresis.
Compared with values before AVT, patients with SVR had a significant decrease in ALT levels (p = 0.005), and DAS28 (p = 0.02) at the end of follow up. Biochemical response was significantly related to viral response (p = 0.02) ( Table 4) , while clinical response (p = 0.4) and joint response (p = 0.4) were not. Joint response was significantly related to DAS28 interpretation before AVT (p = 0.01). Clinical response was significantly related to ESR before AVT (p = 0.01) and RF (p = 0.02), but not significantly related to cryoglobulins (p = 0.3). ALT was positively correlated with PCR count before AVT (p = 0.000, r = 0.6) and after treatment (p < 0.0001, r = 0.6). Steroids, immunosuppressive drug use and plasmapheresis did not affect clinical response (p = 0.07, 0.2, 0.7 respectively), nor did they affect viral response (p = 0.3, 0.1, 0.1 respectively). Antiviral treatment developed some minor side effects in 13 (48.1%) patients such as anemia (n = 5), mild thrombocytopenia (n = 8), flu-like symptoms (n = 7) and mild depression (n = 1). After a mean follow up of 16.5 months (range 6-30 months) 26 of 27 patients were alive and continued to be followed up as outpatients. One patient with polyarteritis nodosa (PAN) died (3.7%) 11 months after the last dose of Peg-IFN due to rapid rising creatinine. She was a clinical and virological non-responder.
Discussion
An estimated 130-170 million people are infected with hepatitis C worldwide leading to significant morbidity, mortality, and financial burden on healthcare [14] . Out of 100 people who contract the infection, 75-85% will develop chronic infection, 60-70% will develop chronic liver disease, 5-20% will develop cirrhosis over the course of their chronic infection, and 1-5% will die of complications including hepatocellular carcinoma (HCC) [15] . Egypt faces the largest burden of HCV infection in the world with a 10% prevalence of chronic hepatitis C infection among persons aged 15-59 years, predominantly genotype 4 [16] . The HCV epidemic is particularly devastating in Egypt where the prevalence of HCV infection is about 12% [4, 5] . Because of its ability to activate the immune system yet avoid elimination, chronic infection can result in accumulation of immune complexes and stimulate antibodies, which can result in extrahepatic conditions [17] . The many rheumatologic manifestations associated with chronic HCV infection include arthralgia, myalgia, arthritis, vasculitis, and sicca syndrome [18] . This was in agreement with the findings of the work of El Garf et al. [19] who studied the prevalence of anti-HCV antibodies among patients admitted to the rheumatology department, Cairo University hospitals over a 6-month period. They found that the rheumatic manifestations of chronic HCV represent the primary cause of admission in 7% of all admitted patients. HCV screening should be included in the routine investigations for patients presenting to rheumatology departments in countries with a high prevalence of chronic HCV infection. The goal of antiviral HCV therapy is to cure the infection. This aim can be achieved in a great number of patients with combination treatment of pegylated interferon and ribavirin [11] . HCV therapy has been revolutionized by the approval of two direct-acting antiviral agents for use in genotype 1 HCV, the protease inhibitors boceprevir and telaprevir [12] . This study aimed to assess the efficacy and safety of combined pegylated interferon and ribavirin therapy in the management of rheumatological EHMs in HCV patients.
The result of this study revealed that 15 patients (55.5%) had SVR, but only two patients (7.4%) were complete clinical responders (CR), 5 (18.5%) were partial responders (PR), 3 (11.1%) showed relapse and 17 (63%) were non-responders (NR). Also, although biochemical response was significantly related to viral response (p = 0.02); clinical response (p = 0.4) and joint response (p = 0.4) were not. Joint response revealed: 2 patients only (8.7%) had a good joint response, 7 (30.4%) had a moderate response, while 14 (60.8%) had no response.
In our study 23 patients had joint arthropathy (85.5%). 13/23 patients (56.5%) had bilateral symmetric non-deforming polyarthritis and 10 (43.4%) had asymmetric oligoarthropathy. Their DAS 28 ranged from 3.5 to 7.7 (5 ± 1.2). Most of these patients were from the Rheumatology and Rehabilitation outpatient clinic and inpatient department, Faculty of Medicine, Cairo University Hospitals; this is possibly responsible for a higher incidence of frank arthritis in our study population, along with a more severe form of disease than that reported by others [20] . In our study, a comparison of DAS 28 score interpretations before and after antiviral treatment among the 23 patients with joint arthropathy revealed: 2 patients (8.6%) had a good joint response, 7 (30.4%) had a moderate joint response, while 14 (60.8%) had no response and in 9 (39.1%)of those 14 patients DAS 28 after AVT was worse than before starting it. Similar to our results, in 2005 Nissen and his colleagues [12] performed a retrospective study on 62 patients with rheumatological manifestations of hepatitis C, they concluded that 45 (72.5%) had received interferon-alpha and 39 responded to the question on its clinical effects. Only three (7.7%) reported an amelioration, 12 (30.8%) no change, 14 (35.9%) an aggravation and the final 10 (25.6%) developed new inflammatory rheumatological symptoms [12] . In our study, of the five patients with mixed cryoglobulinemic vasculitis; two only had SVR and their cryglobulins became negative, yet all of them showed no clinical response. These results were consistent with those of Levine et al. [21] and Landau et al. [22] who concluded that patients may show the persistence of cryoglobulins or symptoms even after the clearance of HCV RNA. These results differ from that in a larger study by Saadoun and his colleagues [23] ; who found different clinical response rates with AVT; Terrier and Cacoub [24] stated that virologic response to combined Peg-IFN and ribavirin is 50-60%. Also, Mazzaro et al. [25] and Cacoub et al. [26] demonstrated that in HCV-associated mixed cryoglobulinemia combined Peg-IFN + RBV therapy leads to a SVR rate similar to that of HCV-infected patients without, and strongly suggested this combination as the first-line treatment for MCS patients. Antiviral treatment is sometimes associated with major immune-mediated adverse events, such as peripheral sensorymotor neuropathy, thyroiditis, rheumatoid-like polyarthritis, and other vasculitic manifestations [27] [28] [29] [30] [31] [32] . In the study of Ta˘na˘sescu and Ionescu [33] , they reported that the most frequent EHM encountered as a result of the interferon therapy were peripheral neuropathy and articular involvement and sometimes rheumatoid-like arthritis. These results were in agreement with our study after AVT. Similar to our results, Pietrogrande and associates reported that the presence of cryoglobulins did not affect the response to AVT [34] . However, clinical peripheral neuropathy was reported to be of high prevalence (45%) in another study on 80 newly diagnosed Egyptian HCV patients, and was found to be associated with cryoglobulinemia; 18 (22.5%) had subclinical neuropathy [35] .
To conclude, the use of Peg IFN and ribavirin did not improve HCV rheumatological extrahepatic manifestations. Antiviral treatment may also induce or worsen autoimmune disorders and is sometimes associated with major immune-mediated adverse events. For this reason this approach should be prescribed only when required by the coexistent liver disease and should be very carefully administered to patients with mixed cryoglobulinemia-related peripheral neuropathy or active skin ulcers.
